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Abstract Overexpression of p53 tumor suppressor protein
in malignant cells induces cell cycle arrest, or alternatively,
apoptosis thereby indicating that additional factors may
contribute to the p53-mediated outcome. Comparison of the
experimental protocols revealed that the construct encoding
wild-type (wt) p53 was expressed in cells of different
origin. Therefore, we decided to determine whether the
intrinsic cellular program of primary cells of the same
genetic background could have any effect on the oncogenic
potential of mutated c-Ha-RAS and TP53. Primary rat cells
(RECs) isolated from rat embryos of different age: at
13.5 gd (y) and 15.5 gd (o), were used for transfection.
Immortalized rat cell clones overexpressing temperature-
sensitive (ts) p53
135val mutant and transformed cell clones
after co-transfection with oncogenic c-Ha-Ras, were gener-
ated. The ts p53
135Val mutant, switching between wt and
mutant conformation, offers the possibility to study the role
of p53 in cell cycle control in a model of malignant
transformation in cells with the same genetic background.
Surprisingly, the kinetics of cell proliferation at non-
permissive temperature and that of cell cycle arrest at
32°C strongly differed between cell clones established from
yRECs and oRECs. Furthermore, the kinetics of the re-enter
of G1-arrested cells in the active cell cycle strongly differed
between distinct cell clones. Finally, the susceptibility of
immortalized and transformed cells to the pharmacological
inhibitors of cyclin-dependent kinases (CDKs) considerably
differed. Our results clearly show that overexpression of
genes such as mutated TP53 and oncogenic c-Ha-RAS is
not able to fully override the intrinsic cellular programme.
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Abbreviations
CDKs cyclin-dependent kinases
FPTase farnesylproteintransferase
FTI inhibitors of FPTase
HH Hedgehog
MDM-2 mouse double minute-2
OLO olomoucine
PARP-1 poly(ADP-ribose) polymerase-1
PD Petri dish
PDT population doubling time
PI propidium iodide
REC rat embyonal cell
ROSC roscovitine
SD standard deviation
ts temperature-sensitive
wt wild-type
Introduction
The decision of a cell to stop cell cycle progression and to
initiate the repair of (mildly) damaged DNA, or to induce
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bears fundamental implications on the future development,
well-being,andfate ofthewholeorganism.Incaserepairdoes
notfunctionproperlyortheinductionofapoptosisisimpaired,
neoplastic transformations arising from damaged DNA, might
culminate in the death of the whole organism. Consequently,
in the case of apoptosis a single cell is sacrificed to facilitate
the survival of the being. Therefore, an extremely sophisticat-
ed cellular network protects the integrity of the genome and
induces the necessary steps once this integrity is disrupted.
At the interface between the incoming intra- and
extracellular signals and the downstream induction and
execution of cell cycle arrest and apoptosis, higher
eukaryotic cells have a molecule of paramount importance:
the p53 tumor suppressor protein. In most cases of cellular
damage p53 is involved in the decision to trigger cell cycle
arrest or apoptosis. Additionally, p53 is involved in all 5
major pathways for DNA repair [2, 20, 26, 35]. The fact
that p53 is inactivated in a wide variety of tumors,
underscores its importance and makes it an outstanding
candidate for cancer therapy [3, 34].
p53 transmits its signals through transactivation of target
genes but also through direct binding to other proteins. In
the cell, p53 levels rise as a result of certain stress stimuli
but are otherwise kept low due to the action of a negative
feedback loop with MDM2. If the action of p53 is needed, a
variety of proteins disrupt the interaction between p53 and
MDM2 [29]. A protein strongly contributing to the stability
of p53 is poly(ADP-ribosyl) polymerase-1 (PARP-1) [38,
42, 43], a protein that enzymatically modifies p53 [19, 41]
thereby preventing its nuclear export [19, 39]b yi m p e d i n g
the binding to CRM1 [19]. A protein that retains p53 in the
cytoplasm preventing its nuclear functions, is mortalin, a
memberoftheheatshockprotein70(HSP70)family.Mortalin
binds p53 [31] and inhibits its pro-apoptotic functions what
leads to increased tumor development [31, 37].
The constitutive overexression of p53 in cells or animals is
not feasible because this would trigger apoptosis or at least cell
cycle arrest, making a functional study of the proteins’ features
impossible. Fortunately, a temperature-sensitive (ts) mutant of
p53 that displays wt properties at 32˚C but mutant character at
elevatedtemperature[25], can be used to perform experiments
aimed to elucidate its functions. This ts mutant demonstrates
clear properties of mutant p53 at 39°C. At 37°C the cells also
behave like mutant cells although a small portion of p53
protein is in wt conformation. However, mutated p53 protein
localized in the cytoplasm impedes the action of the wt
protein. Thereby, the conformation and activity of p53 can be
changed at will by simply growing the cells at 37 or 39˚C.
The decision of p53 to trigger cell cycle arrest or
apoptosis depends on the severity of the damage and is also
regulated on the transactivational level by the use of p53
responsive elements to which the protein has different
binding affinity [16]. In general, p53 binds to targets
mediating cell cycle arrest with a higher affinity than to
those which induce apoptosis [16]. A recent publication
also showed that p53 is capable of inducing anti-apoptotic
targets [17], adding further complexity to the functions and
activities of the tumor suppressor protein.
Also the Ras proteins are important for tumor develop-
ment. In their active form they reside in the cytoplasmatic
membrane and transmit signals from growth factor stimu-
lation and downstream targets involve Raf-1 and PI3-
kinase. Gain of function mutations lead to a constitutively
active Ras protein that sustains growth-promoting signals,
irrespective of extracellular stimulation, resulting in uncon-
trolled proliferation. For its proper anchoring in the
cytoplasmic membrane and activity, Ras has to be iso-
prenylated by farnesyl protein transferases (FPTases) or/and
geranylgeranyl protein transferases. Therefore, inhibitors of
farnesylation have been used for treatment of cancers with
constitutively activated RAS. Interestingly, tumor cells with
constitutively activated RAS are rendered prone to treatment
with pharmacological inhibitors of cyclin-dependent
kinases (CDKs) like roscovitine (ROSC) and olomoucine
(OLO) when they are pre-treated with FTIs [45].
To test the responsiveness of cells overexpressing c-Ha-
Ras and ts p53, we used primary rat embryonal cells
(RECs) isolated at 13.5 or 15.5 gestation days. Importantly,
the age of the embryos seems to have an effect on the
properties of the cells [30]. In the present work we
investigated the effect of the cellular microenvironment in
young vs old RECs in response to combined treatment with
FPTase inhibitors and CDK inhibitors.
Material and Methods
Plasmids
pLTRp53cGval135, comprising a chimera of mouse p53
cDNA and genomic DNA (generous gift of Dr. M. Oren),
has been previously referred to as pLTRp53cG [6]. It
encodes a mutant protein harboring a substitution from
alanine to valine at the amino acid in position 135. The
plasmids pVV2, bearing the neomycin resistance sequence,
and pVEJB coding for a mutated human c-Ha-Ras gene
cloned into pVVJ were used.
Cell Clones
The transformed rat cell clones were established as previously
described in detail [40] using primary Fisher rat embryo cells
(RECs). RECs were obtained from embryos isolated at 13.5
(y) and 15.5 (o) gestation days. Cells were grown at basal
temperature (37°C) in DMEM supplemented with 10% FCS
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a change of the conformational state of p53 protein, cells
grown at basal temperature, were shifted to 32°C for
indicated periods of time.
Drugs
Olomoucine (OLO) and roscovitine (ROSC) were prepared
as 50 mM stock solution in DMSO according to
the published procedure [14]. Aliquots of the stock
solution were stored until use at -20°C. Furthermore,
L-744,832 [(2 S)-2-[[(2 S)-2-[(2 S,3 S)-2-[(2R)-2-amino-
3-mercaptopropyl]amino]-3-methylpentyl]oxy]-1-oxo-3-
phenylpropyl]amino]-4-(methylsulfonyl)-butanoic acid
1-methylethyl ester ] an inhibitor of protein farnesyltrans-
ferase (FTI) from Alexis Biochemicals (Lausen, Switzer-
land) was used. The stock solution of L-774,832 was
prepared in DMSO. Aliquots of stock solutions were
protected from light and stored until use at -20°C.
Cell Treatment
After plating, cells were cultivated at a basal temperature of
37°C for 24 h. Then drugs were added to a final concentration
as indicated. Cells were incubated continuously for 24 h or
48 h, or alternatively, after 24 h treatment medium was
changed and cells were post-incubated (p. i.) in a drug-free
medium for a further 24 h or 48 h. In some experiments cells
wereshiftedto32°Candkeptthereforatleast24hpriortothe
onset of treatment to allow p53 to adopt wt conformation.
Determination of Population Doubling Time
To determine the kinetics of the proliferation of distinct cell
clones, cells were plated into PD of 6 cm diameter. For each
time point two PDs were used. Immortalized cells were
plated at a medium density (2×10
5) and transformed cells
at a lower density (0.5×10
5/PD). Cells were cultivated at a
basal temperature for 5 days. PDs were collected in 12 h
intervals, suspended in a defined volume of medium and
were counted in a cell counter (CASY). Cell number was
determined in at least two distinct aliquots of cell
suspension collected from each PD.
Determination of the Number of Viable Cells
Proliferation of immortalized and transformed control rat
cells and their sensitivity to increasing concentrations of the
CDK inhibitor ROSC were determined by the CellTiter-
Glo
TM Luminescent Cell Viability Assay (Promega Corpo-
ration, Madison, WI). As described recently in more detail
[44], the CellTiter-Glo
TM Luminescent Cell Viability
Assay, generating a luminescent signal, is based on
quantification of the cellular ATP levels. Tests were
performed at least in quadruplicates. Luminescence was
measured in the Wallac 1420 Victor, a microplate lumines-
cence reader. Each point represents the mean ±SD (bars) of
replicates from at least four experiments.
Determination of Caspase-3/7 Activity
The activity of both caspases was determined using the
APO-ONE Homogenous Caspase-3/7 Assay (Promega,
Madison, WI) which uses the caspase-3/7 substrate rhoda-
mine 110, bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-
L-aspartic acid amide) (Z-DEVD-R100) as described
previously [44]. Briefly, rat cells were plated in 96-well
microtiter plates. One day after plating the cells were
exposed for 24 h to increasing drug concentrations.
Thereafter, culture supernatant was transferred into another
microtiter plate to separately determine the caspase activity
in cells and in culture medium. Then an equal volume of
caspase substrate was added and samples were incubated at
37°C for different periods of time to assess the best signal-
to-background ratio. The fluorescence was measured at
485 nm. Luminescence and fluorescence were measured in
the Wallac 1420 Victor, a microplate luminescence reader.
Each point represents the mean ± SD (bars) of replicates
from at least three experiments.
Measurement of the DNA Content of Single Cells by Flow
Cytometry
The measurement of DNA content was performed by flow
cytometric analysis based on a slightly modified method [38]
described previously [36]. The cells were detached from
substratum by trypsinization, and then all cells were harvested
by centrifugation and washed in PBS. Aliquots of 1×10
6
cells were used for further analysis. Cells were stained with
propidium iodide (PI) as described, previously [39]. Fluores-
cence was measured using the Becton Dickinson FACScan
after at least 2 h incubation of the cells at +4°C in the dark.
Results
Differential Proliferation Rate of y and o Immortalized
Rat Cells
In the first step the proliferation rate of primary rat cells and
four studied cell clones were determined. Cells plated in the
defined cell density were cultivated for 5 days at a basal
temperature. Cell numbers were determined in 12 h
intervals by two different methods. First, cells were counted
using an automatic cell counter and in parallel numbers of
living cells were determined by the CellTiter-Glo
TM
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Madison, WI). As described recently in more detail [44],
the CellTiter-Glo
TM Luminescent Cell Viability Assay,
generating a luminescent signal, is based on quantification
of the cellular ATP levels. Both methods gave comparable
results within the first 3 days; later CellTitert-Glo under-
estimated the numbers of transformed cells. The primary
cells isolated from rat embryos (RECs) at gestation
day 13.5 (y) grew much slower than those isolated at
day 15.5 (o) [30]. The population doubling time (PDT)
calculated from growth curves for the oRECs was approx-
imately 2-fold shorter than that for yRECs (Table 1).
RECs transfected with ts p53
135Val mutant alone, or
simultaneously with human c-Ha-RAS, generated immor-
talized and transformed cells, respectively. As described
previously [30], the phenotype of immortalized cells
resembled that of primary cells. However, in contrast to
RECs, cells expressing ts p53
135Val got over the Hayflick
limit and did not undergo senescence. Cotransfection with
c-Ha-RAS resulted in a clear change of cell morphology to
spindle-shaped [30] and conferred the generated cell lines a
high mitotic potential. The features of transformed cells
were also functionally proved. After subcutaneous injection
of cells overexpressing p53
135Val +c-Ha-Ras into rats large
tumors appeared within approximately 2 weeks [30].
As shown in Fig. 1, the transformed cells divided very
rapidly. Interestingly, the immortalized and transformed cell
lines originating from oRECs (clone 602/534 and 173/
1022), divided at 37°C much more rapidly than those from
yRECs (clone 402/534 and 189/111). The population
doubling time (PDT) was calculated for each cell clone
from the growth curves. As depicted in Table 1, even
immortalization of yRECs with ts p53
135Val mutant (clone
402/534) did not confer them high mitotic potential at non-
permissive temperature. On the other hand, the proliferative
potential of their counterparts generated from oRECs was
markedly higher. Interestingly, the same trend was observed
in transformed cell lines after co-transfection with c-Ha-
RAS. However, during the time period between 24 h and
48 h after cell plating, the transformed cells did not gain the
full dividing capacity. The difference in the proliferation
rate between transformed y and o cell clones became
evident 48 h after cell plating (Fig. 1).
Kinetics of wt p53-Mediated Cell Cycle Arrest Differs
Between Cell Clones Generated in y and o Embryonal
Rat Cells
In accordance with previous reports, in cells overexpressing
ts mutant p53
135Val, the protein switches conformation after
temperature shift to 32°C and as a consequence, cells start
to accumulate in G1 phase of the cell cycle (Fig. 2). The
induction of cell cycle arrest after temperature shift to 32°C
was observed solely in cells expressing ts mutant p53
135Val
but not in cells overexpressing c-myc + c-Ha-Ras (our
unpublished data) and was associated with the translocation
of p53 protein from the cytosol to the nucleus [30, 37, 41].
Moreover, primary yRECs and oRECs lacking the ts
mutant and expressing endogenous p53 at low concen-
trations failed to accumulate in G1 phase after maintenance
at 32°C [30]. These observations substantiate the assump-
tion that the temperature-dependent block of cell prolifer-
ation and of the cell cycle progression at permissive
temperature is attributable to ts p53 mutant and evidence
that the experimental system functions properly.
Table 1 Comparison of the values of the population doubling times
(PDTs)
Cells Age of RECs Overexpressed proteins PDT [h]
Rat embryonal cells (RECs)
yRECs 13.5 gd - 85.8
oRECs 15.5 gd - 44.8
Cell clones
402/534 13.5 gd p53
135Val 32.07
602/534 15.5 gd p53
135Val 14.20
189/111 13.5 gd p53
135Val c-Ha-Ras 11.52
173/1022 15.5 gd p53
135V\al c-Ha-Ras 11.16
The increase of the cell numbers within the time period between 24 h
and 48 h after plating was used for determination of the PDT
Fig. 1 Kinetics of proliferation of immortalized and transformed rat
cells. Immortalized (402/534 and 602/534) and transformed (189/111
and 173/1022) cell clones established in RECs from embryos at 13.5
(y) and 15.5 (o) gestation days were examined. The growth curves of
immortalized and transformed RECs from young (402/534 and 189/
111) and old (602/534 and 173/1022) embryos at basal temperature
are shown. Cells were counted in a cell counter (CASY). Each point
represents the mean of four cell aliquots ± SD. Transformed cells grow
faster than primary cells. The cells originating from older embryos
always grow faster than their counterparts from young embryos.
Population doubling time (PDT) for each cell line is shown in Table 1.
402/534 - yRECs p53
135Val; 602/534 - oRECs p53
135Val; 189/111 -
yRECs p53
135Val + c-Ha-Ras; 172/1022 - oRECs p53
135Val + c-Ha-Ras
S218 J. Węsierska-Gądek et al.Fig. 2 Intrinsic features of
RECs determine the p53-
mediated cell cycle regulation.
DNA profile obtained from one
representative experiment.
Young immortalized (first
horizontal row), old immortal-
ized (second horizontal row),
young transformed (third
horizontal row) and old trans-
formed cells (fourth horizontal
row) were cultivated at 37˚C for
24 h and then shifted to 32˚C for
24 h. DNA concentration in
single cells was determined by
flow cytometric analysis of
PI-stained cells. DNA histo-
grams were prepared using the
CellQuest evaluation program
(upper panel). The frequency of
diploid cells in the distinct cell
cycle phases was determined
using the ModFit evaluation
program (lower panel)
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population of S-phase cells was strongly reduced in all four
cell lines. However, the frequency of the G2/M population
varied between them. The comparison of the time course of
the cell cycle changes revealed considerable differences in
the kinetics of the cell cycle arrest at permissive tempera-
ture as shown in Fig. 3. The immortalized 402/534 cells
were almost completely arrested in G1 after 24 h at 32°C,
whereas in 602/534 cells only S-phase, but not G2 phase
was diminished (Fig. 3, upper panel). In contrast, trans-
formed cells (clone 173/1022) generated from oRECs,
showed a stronger response to the temperature shift.
G1-arrested, Transformed Rat Cells Re-enter more Rapidly
the Active Cell Cycle than their Immortalized Counterparts
In the next series of experiments we addressed the question
whether the endogenous features of primary cells used for
establishment of cell lines might display any effect on the
recovery of G1-synchronized cells in the active cell cycle.
We maintained all cell clones for 24 h at permissive
temperature and then shift e dt h e mb a c kt ot h eb a s a l
temperature. As depicted in Fig. 4, transformed cells
entered the active cell cycle more rapidly than the
immortalized cells. Surprisingly, the kinetics of cell cycle
recovery strongly differed between cell lines derived from y
and o RECs. In the latter a pronounced increase of S-phase
cells was observed 6 h after elevation of temperature and
after a further 6 h the ratio of DNA-replicating cells was
approximately 70%. Moreover, maintenance of examined
rat cells at permissive temperature slightly increased the
ratio of sub-G1 cells indicating that this subset of cells
represents apoptotic cells. To check it, the activity of
caspase-3/7 was determined. A moderate elevation of the
activity of effector caspases was observed in 402/534 and
189/111 cells (data not shown) confirming the assumption
that at permissive temperature wt p53 may induce apoptosis.
The Pharmacological Inhibitors of CDKs Stronger Affect
Transformed Rat Cells Established from Primary Cells
Isolated at 13.5 gd than Cells Isolated at 15.5 gd
To determine the effect of both examined CDK inhibitors
on the proliferation of exponentially growing transformed
rat cells, the cells were continuously exposed to the drugs
for 24 h or 48 h. Then the cell number was determined
using the CellTiterLumiGlo viability assay immediately
upon termination of the treatment, or alternatively the
medium was changed, cells were post-incubated in a drug-
free medium for further 1 or 2 days, and then the assay was
performed. OLO is a weaker inhibitor of CDKs than ROSC
[14] and therefore we used it at a higher dosage. As
expected, ROSC stronger reduced the number of living cells
than OLO. Moreover, transformed cells established from
primary rat cells isolated at 13.5 gd (189/111 cells) were
more sensitive to the inhibition of CDKs than their counter-
parts generated from 15.5 gd RECs (173/1022) (Fig. 5).
Exposure of 189/111 cells to ROSC at a final concentration
of 20 µM reduced the number of living cells by approxi-
mately 30% and the number of 173/1022 cells by approx-
imately 15%. The anti-proliferative effect of ROSC at higher
Fig. 3 Kinetics of the cell cycle arrest in the permissive (32°C)
temperature. The FACS analyses show the cell cycle distribution of
immortalized, and transformed cells originating from young (left
panels) and old (right panels) RECs at 32 and 37˚C. oRECs more
efficiently evade cell cycle arrest than yRECs in all groups. As
expected, immortalized cells show stronger growth than primary cells
and transformed cells exhibit the strongest growth. The frequency of
diploid cells in the distinct cell cycle phases was determined using the
ModFit evaluation program. The values represent the means of three
independent experiments ± SD (bars)
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treatment for 24 h (Fig. 5) and 48 h (data not shown).
Inhibition of c-Ha-Ras Processing Sensitizes Transformed
Rat Cells Established from oRECs to CDK Inhibitors
Further, we addressed the question whether the activity
status of overexpressed oncogenic c-Ha-Ras might have
any effect on the susceptibility of transformed rat cells to
tested CDKs inhibitors. To gain full biological activity, Ras
proteins after de novo s y n t h e s i sh a v et ob es t e p w i s e
modified. Isoprenylation, catalyzed by farnesyl protein
transferase (FPTase), is the first reaction in this series of
events. Both cell lines were treated for 24 h with L-
744,832, a pharmacological inhibitor of FPTase (FTI) alone
or in combination with OLO or ROSC. Then the number of
living cells was determined immediately or alternatively,
medium was changed and cells were post-incubated for
24 h in a drug-free medium or with FTI. The inhibition of
isoprenylation had a stronger anti-proliferative effect on
173/1022 than on 189/111 cells (Fig. 6). Addition of FTI to
ROSC enhanced its inhibitory effect on 173/1022 cells. The
strongest reduction of the number of viable 173/1022 cells
occurred after post-incubation for 24 h in the presence of
FTI (Fig. 6).
Taken together, our above results show that immortal-
ized and transformed cell lines established from primary
cells isolated from older embryos (15.5 gd) had a
proliferation advantage over their counterparts isolated
from younger embryos (13.5 gd) associated with less
susceptibility to therapy. It seems that c-Ha-Ras, when
overexpressed in oRECs, contributes to their lower suscep-
tibility to synthetic CDK inhibitors.
Discussion
For investigations concerning tumor development and also
the treatment of cancer, the analysis of properties from
tumor suppressor proteins as well as from oncogenes is of
paramount importance. Since the TP53 and RAS genes are
two of the most frequetly affected targets during neoplastic
transformation in a wide variety of cells and tissues [11, 13],
we focused our research presented here, on these two
molecules. The RAS proto-oncogene is often mutated, leading
to a constitutively active form and p53 is usually inactivated
or expressed as a dominant negative protein in tumors.
Most importantly, inactivated TP53 and mutated c-Ha-
RAS act synergistically in making cells vulnerable to
chemically induced carcinogenesis in vitro and also in vivo
[47, 48]. The ts p53 used in our work was shown to
synergistically induce malignant transformation together
with c-Ha-Ras in primary RECs [12]. Hemizygosity in
p53 leads to clear signs of haploinsufficiency [10, 15]a n d
germ line mutations in humans are known as Li-Fraumeni
syndrome [23] leading to multiple cancers with poor
prognosis [7]. The synergistic action of mutated TP53 and
c-Ha-RAS in tumor development and progression [32, 47]
is not surprising, considering that p53 protein usually
arrests the cell cycle of damaged cells or induces
apoptosis, and Ras is able to transmit extracellular,
Fig. 4 Temperature-dependent kinetics of proliferation of primary,
immortalized, and transformed rat cells. RECs were isolated from
embryos at 13.5 (y) and 15.5 (o) gestation days. The growth curves of
primary, immortalized, and transformed RECs from young (left
vertical row) and old (right vertical row) embryos at three different
temperatures are shown. Immortalized cells grow faster than primary
cells and transformed cells grow fastest. The cells originating from
older embryos always grow faster than their counterparts from young
embryos. The values represent the means of three independent
experiments ± SD (bars)
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pathway [21].
Several isoforms of the two other members of the
p53 family, p63 [46]a n dp 7 3[ 4], have overlapping
functions with p53 and some isoforms have rather opposing
functions. Therefore, these proteins are important for fine-
tuningandplayadditionalrolesinearlydevelopment,butthey
are not able to take over the functions of inactivated p53.
In the present work we used primary, immortalized (ts
p53), and transformed (ts p53 and c-Ha-Ras) RECs from
young (13.5 gd) and old (15.5 gd) embryos to compare
their growth potential and their susceptibility to treatment
with FPTase inhibitors and CDK inhibitors. At the basal
temperature (37˚C; p53 inactive) the immortalized and
transformed cell lines originating from oRECs (clones 602/
534 and 173/1022, respectively) showed a clearly elevated
growth potential as compared to their counterparts from
yRECs (402/534 and 189/111, respectively). Not surprisingly,
transformed cells in both cases grew faster than immortalized
cells from the same kind of embryos (y vs o). Apparently,
epigeneticchangestakeplacebetween13.5and15.5gestation
days, leading to an elevated potential of cells from older
embryos to overcome growth arrest.
Next we tested the effect of the CDK inhibitors
roscovitine and olomoucine on transformed cells from
young and old embryos. The transformed cells from young
embryos were more sensitive to treatment with CDK
inhibitors than their counterparts from older embryos. Most
importantly, following prior treatment with an FPTase
inhibitor that inactivates c-Ha-Ras, also transformed cells
from older embryos were strongly susceptible to the
growth-inhibiting effect of CDK inhibitors. These results
show, that c-Ha-Ras contributes to the partial resistance of
transformed cells from oRECs to the action of CDK
inhibitors. A thorough scrutiny of the exact mechanistic
background for the differences in the behaviour of the
mentioned cell types should shed additional light on the
cellular basis for the described effects.
In distinct stages of embryonic development tissue
homeostasis is modulated by a balance between proliferation
and programmed cell death. A temporally and spatially
regulated apoptosis is essential for differentiation and matu-
ration of different tissues and plays an important role,
especially in neurogenesis. The increase of apoptotic events
occurs in mid stages of embryonic development. Analyses of
rat fetuses from the biologically most interesting stages
revealed differences in the expression of some important
proteins including CDK5 [5, 27] or alpha-fetoprotein [24].
The epigenetic changes between 13.5 and 15.5 gestation
days seem to allow a synergistic action of mutated p53 and
c-Ha-Ras to overcome cell cycle arrest and facilitate the cell
to pass through the whole cell cycle. Presumably, the
Fig. 5 The pharmacological inhibitors of CDKs stronger affect
transformed rat cells established from primary cells isolated at
13.5 gd than from cells isolated at 15.5 gd. Transformed cells were
plated into 96 well microtiter plates (two plates for each condition).
One day after plating, cells were exposed to drugs for 24 h or for 48 h
(not shown). Thereafter, the number of viable cells was determined
using CellTiterGlo. Tests were performed at least in quadruplicate.
Luminescence was measured in the Wallac 1420 Victor, a multilabel,
multitask plate counter. Each point represents the mean ± SD (bars)o f
replicates from three independent experiments. Statistical analysis was
performed using GraphPad Prism and significance levels were
evaluated using T test
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chromatin remodelling and/or the Ras/Raf/MEK/ERK
pathway. Two of the candidates that are also important in
embryonal development are the Wnt/catenin and the
Hedgehog (HH) pathways. Since the HH pathway is also
connected to the K-Ras pathway [18, 28] and plays a central
role in the embryonal patterning during the phase under
scrutiny, it is our prime candidate. HH regulates embryonal
patterning through gradients of its 3 isoforms, however, in
some adult tissues HH is also responsible for homeostasis
and has effects on cell proliferation and apoptosis. Most
importantly, deregulated HH can also lead to cancer
development [1, 22, 33] and cyclopamine, an inhibitor of
the HH pathway, is able to reduce metastasis [8, 9].
At 32˚C ts p53 adopts wt conformation and cells
accumulate in G1 phase of the cell cycle. The ratio of cells
in S phase was strongly reduced in all tested cells. The
immortalized cells from young embryos (402/534) were
nearly completely arrested in G1 phase after 24 h at 32˚C,
whereas the immortalized cells from older embryos (602/
534) showed a reduction in S phase, but not in G2 phase
pointing to a different regulation in both cell types.
However, transformed cells from oRECs showed a stronger
response to the temperature shift. After shifting the cells
back to 37˚C, transformed cells from oRECs re-entered the
cell cycle much faster then transformed cells from yRECs.
As expected, transformed cells entered the cell cycle more
quickly than their immortalized counterparts.
The most salient finding of our present work is the
strong impact of the endogenous cell traits in o vs y RECs.
Our results show that even strong oncogenes such as
mutated c-Ha-RAS and mutated TP53 are not able to
override the intrinsic cellular program. Taken together, our
results show that transformed RECs from older embryos
show a higher growth potential than their counterparts from
yRECs and are less susceptible to the action of CDK
inhibitors. However, after inactivation of c-Ha-Ras with an
inhibitor of farnesylation, also the transformed oRECs are
strongly susceptible to growth inhibition by CDK inhib-
itors. If the phenotype of a certain tumor is known, this
knowledge might help to develop a customized treatment
for tumors with constitutively activated Ras.
Fig. 6 Inhibition of c-Ha-Ras processing sensitizes transformed rat
cells established from oRECs to CDK inhibitors. Transformed cells
were plated into 96 well microtiter plates (two plates for each
condition). One day after plating, cells were exposed to indicated
drugs for 24 h. Thereafter, the number of viable cells was determined
in the first microtiter plate. In the second microtiter plate medium was
changed (MC) and cells were post-incubated (p.i.) for a further 24 h in
a drug-free medium or with FTI. The measurement of the number of
viable cells immediately after treatment for 24 h provided information
on the direct cytotoxic effect of the drug. On the other hand, post-
incubation of cells treated for 24 h, for another 48 h in a drug-free
medium, allowed the evaluation of the long-term effects of the
treatment. Tests were performed at least in quadruplicate. Lumines-
cence was measured in the Wallac 1420 Victor, a multilabel, multitask
plate counter. Each point represents the mean ± SD (bars) of replicates
from three experiments. Statistical analysis was performed using
GraphPad Prism and significance levels were evaluated using T test
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